Here’s what it means for you moving forward.
Due to high volumes of customer enquiries, we’re experiencing longer response times than usual. Read our dedicated webpage for the latest updates → Mounjaro Price Changes
Eli Lilly, the manufacturer of the weight loss medication Mounjaro, has announced a cost increase that will come into effect across the UK on Monday 1st September 2025. We know this may seem worrying, but our top priority is making sure your progress and momentum are protected.
Here’s what it means for you as a Numan patient and how we’re going to be supporting you over the coming weeks and months.
Hi Andrew,
We want to reassure you that, whilst prices are changing, your results and ongoing care remain our top priority. So, all September orders will be guaranteed at current prices. See more details on this below.
Impacts every private provider, raising the UK wholesale price by 170%. While a smaller adjustment to our prices may be necessary, we’re fully committed to supporting the progress you’ve already made and helping you to continue your treatment journey. We’re working hard to confirm the best possible options for you, and we’ll continue to share these with you as they evolve, alongside any pricing adjustments.
Wegovy, a GLP-1 medication, continues to be a cost-effective option for our patients. It drives an average of 17.5% body weight loss¹, as well as being clinically proven to reduce appetite, cravings, and risk of cardiovascular disease².
If you’d like to switch to Wegovy, fill out the form below to submit a medication change request and, if it’s accepted, your new treatment will be delivered with clear guidance.
You can switch to Wegovy without taking an extended break. As long as you stop taking Mounjaro completely, it’s safe to start Wegovy at the time your next Mounjaro dose would have been due.
Over the coming days and weeks, we will keep you updated with the latest information so you have everything you need to make decisions with the utmost confidence. Keep a close eye on your inbox for more details.
Your current programme will not be impacted until October at the earliest, so you have time to reach out to our clinical team and discuss your plans.
Our Customer Care Team is on hand to provide clarity and guidance at every stage, however, extremely high volumes of patient enquiries are currently causing longer wait times than usual.
We strongly encourage you to take the following steps before contacting us:
Currently, responses to queries can take 24-36 hours. We really appreciate your patience during this busy period and we’ll be in touch again soon.
Best wishes,
Numan Clinical Team
You’re receiving this email because it is an essential update about our service.
¹ Associated uplift in weight loss seen based on a retrospective study in 2,366 patients treated with a weight loss programme including a dual GLP-1 and GIP receptor agonist and a digital behavioural programme. Results seen after 3 months of treatment. Uplift attributed to the digital behavioural programme in patients with no prior use of weight loss medication.
Individual results may vary based on lifestyle, usage of the app, and interactions with behavioural coaching.
² Based on the latest clinical trial data, Mounjaro (tirzepatide) and Wegovy (semaglutide) demonstrate similar weight loss profiles with both treatments leading to substantial reductions in average body weight. Mounjaro has shown a mean weight loss of 20.2% in the SURMOUNT-1 trial, while Wegovy (2.4 mg) achieved 17.5% in the STEP UP trial.
³ Lincoff et al. 'Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes'. NEJM (2023)